Pharmacology of acute lung injury

被引：57

作者：

Tasaka, S

Hasegawa, N

Ishizaka, A

机构：

[1] Tokyo Elect Power Co Hosp, Dept Lab Med, Shinjuku Ku, Tokyo 1600016, Japan

[2] Keio Univ, Sch Med, Dept Med, Tokyo 160, Japan

[3] Nippon Kokan KK, Dept Med, Kawasaki, Kanagawa 210, Japan

来源：

PULMONARY PHARMACOLOGY & THERAPEUTICS | 2002年 / 15卷 / 02期

关键词：

ALI/ARDS; sepsis; pharmacological treatment;

D O I：

10.1006/pupt.2001.0325

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a clinical syndrome that affects both medical and surgical patients. To date, despite improved understanding of the pathogenesis of ALI/ARDS, pharmacological modalities have been unsuccessful in decreasing mortality. However, several pharmacological agents for ARDS are in development and have shown great promise. In addition to the antiinflammatory category including late corticosteroids, inhaled nitric oxide, alveolar surfactant, and vasodilators are being evaluated. Replacements of anticoagulation mediators have also suggested beneficial effects on the patient outcome. This article provides an overview of pharmacological treatments of ALI/ARDS. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：83 / 95

页数：13

共 145 条

[1] Reduced mortality in association with the acute respiratory distress syndrome (ARDS) [J].

Abel, SJC ;

Finney, SJ ;

Brett, SJ ;

Keogh, BF ;

Morgan, CJ ;

Evans, TW .

THORAX, 1998, 53 (04) :292-294

[2] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].

ABRAHAM, E ;

WUNDERINK, R ;

SILVERMAN, H ;

PERL, TM ;

NASRAWAY, S ;

LEVY, H ;

BONE, R ;

WENZEL, RP ;

BALK, R ;

ALLRED, R ;

PENNINGTON, JE ;

WHERRY, JC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941

[3]

Abraham E, 1998, LANCET, V351, P929

[4] Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome:: A controlled, randomized, double-blind, multicenter clinical trial [J].

Abraham, E ;

Baughman, R ;

Fletcher, E ;

Heard, S ;

Lamberti, J ;

Levy, H ;

Nelson, L ;

Rumbak, M ;

Steingrub, J ;

Taylor, J ;

Park, YC ;

Hynds, JM ;

Freitag, J .

CRITICAL CARE MEDICINE, 1999, 27 (08) :1478-1485

[5] p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial [J].

Abraham, E ;

Glauser, MP ;

Butler, T ;

Garbino, J ;

Gelmont, D ;

Laterre, PF ;

Kudsk, K ;

Bruining, HA ;

Otto, C ;

Tobin, E ;

Zwingelstein, C ;

Lesslauer, W ;

Leighton, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19) :1531-1538

[6] Coagulation abnormalities in acute lung injury and sepsis [J].

Abraham, E .

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2000, 22 (04) :401-404

[7]

ABRAHAM E, 2000, AM J RESP CRIT CARE, V161, pA379

[8]

*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801

[9] Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome [J].

Amato, MBP ;

Barbas, CSV ;

Medeiros, DM ;

Magaldi, RB ;

Schettino, GDP ;

Lorenzi, G ;

Kairalla, RA ;

Deheinzelin, D ;

Munoz, C ;

Oliveira, R ;

Takagaki, TY ;

Carvalho, CRR .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (06) :347-354

[10]

[Anonymous], INTENSIVE CARE ME S1

← 1 2 3 4 5 6 7 8 9 10 →